Guggenheim lowers Axsome stock price target to $250 on valuation
Guggenheim reduced Axsome Therapeutics' (AXSM) price target to $250 from $275, maintaining a Buy rating. AXSM's Q3 sales reached $207.6M, up 53% YoY, with strong gross margins. The company reported $259.7M in total revenue, beating estimates, but posted an adjusted loss of $0.25 per share. Analysts remain bullish, with price targets ranging from $238 to $380.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on revenue growth and cash position, while the analyst downgrade introduces new downside risk.
Market read
First report of Q3 2026 results and analyst target changes for AXSM, offering actionable insight for traders.
What to watch
Potential future growth from Auvelity and upcoming ENGAGE trial results could offset short‑term pressure.
Background
Axsome Therapeutics reported strong sales growth in Auvelity and Sunosi, with cash runway extending into 2027.
Ticker impact
Guggenheim lowered its price target on Axsome Therapeutics to $250 from $275 and reported Q3 2026 earnings of $259.7M revenue, a 52% YoY increase.
likely downward pressure as the market prices in the lower target and modest earnings beat
Target reduction signals reduced upside; despite revenue beat, earnings miss and modest guidance keep downside risk.
Market effects
Biotech sector may see broader scrutiny as analyst targets adjust.
US biotech stocks could face modest pullback.
Limited to investors tracking US-listed biotech earnings.
Counterpoint
Some investors may view the revenue beat as a catalyst for upside despite the target cut.
Key entities
- AnalystGuggenheim
Lowered price target to $250.
- AnalystUBS
Also lowered price target to $239.
